Debargha Basuli, MD PhD ретвитнул
Debargha Basuli, MD PhD
71 posts

Debargha Basuli, MD PhD
@DebarghaBasuli
Nephrology Asst Professor @ECUHealth_IM I Transplant Nephrology @OHSUNephrology I
Присоединился Kasım 2021
740 Подписки238 Подписчики
Debargha Basuli, MD PhD ретвитнул

Fluid overload occurs frequently in critically ill patients with AKI and is one of the indications for continuous kidney replacement therapy (CKRT). In this article, the authors state that available and emerging tools help predict and monitor volume status more actively and dynamically to best design UF strategies that avoid hypotension but alleviate congestion. bit.ly/CJASN0650
@GonzaRGuerrero

English

In the presence of a negative immunofluorescence panel, what is your diagnosis?
#DiagnoseThis #renalpath #nephropath

English
Debargha Basuli, MD PhD ретвитнул

KIDNEYcon Registration is Open!
April 6-8, 2024
Little Rock, AR
kidneycon.org/registration
Little Rock will experience the 2024 Total Solar Eclipse
Discount room rates at the DoubleTree Hotel!
@NephroRock @nephrosharma @nephrosingh @VelezNephHepato @kidney_boy
English
Debargha Basuli, MD PhD ретвитнул
Debargha Basuli, MD PhD ретвитнул

DARE-ESKD 1: Pharmacokinetic Properties of SGLT2 inhibitor (SGLT2i) Dapagliflozin in Patients on Hemodialysis and Peritoneal Dialysis ca. 2023 from @CJASN #Nephpearls
- Well tolerated
- Slightly dialyzable
- Non-accumulating pharmacokinetic properties
pubmed.ncbi.nlm.nih.gov/37227937/




Riverside, IL 🇺🇸 English
Debargha Basuli, MD PhD ретвитнул

Looks like you can #Flozinate your dialysis patients!
"In individuals with kidney failure on dialysis, dapagliflozin was well-tolerated, slightly dialyzable, and had non-accumulating pharmacokinetic properties"
journals.lww.com/cjasn/_layouts…

English
Debargha Basuli, MD PhD ретвитнул
Debargha Basuli, MD PhD ретвитнул

Genomics in Glomerular Disease
A GlomCon Pubs summary on genetic diagnoses of glomerular diseases by Dr. Benjamin Tan @NephBen
Read more 👉🏻 pubs.glomcon.org/genomics-in-gl…
#GlomCon

English
Debargha Basuli, MD PhD ретвитнул

Our article in @NatRevImmunol proposes that nephritis can be classified primarily according to cause, then by the lesion. This would improve management, education, understanding and research.
Thanks to @hjanders_hans @PRomagnani and Prof Nelson Leung for a great collaboration.
Nature Rev Immunol@NatRevImmunol
Glomerulonephritis: immunopathogenesis and immunotherapy dlvr.it/Sgmj79
English

@DebarghaBasuli I don’t think so, but you can grab the presentation at sorrymyslidesarentdone.com
English

That is totally what I look like now and not a picture from 15 years ago. Honest.
NCH Kidney Center@NCHKidneyCenter
Please join us for kidney grand rounds as we welcome @kidney_boy via zoom at 1pm EST. All welcome to attend as we learn about acid-base disorders from a master educator. Link to the presentation 👉 bit.ly/3WZnab0 @OhioStateNeph @ASPNeph @IPNA_PedNeph
English
Debargha Basuli, MD PhD ретвитнул

A nice refresher of high yield kidney disorders!
#TBThursday
-md
renalfellow.org/2020/05/21/hig…
English
Debargha Basuli, MD PhD ретвитнул
Debargha Basuli, MD PhD ретвитнул

📌 A very comprehensive stepwise ECG algorithm
👉 to predict site of origin of idiopathic VAs
#ECG #CardioTwitter #EPeeps @adribaran @ECGTalk @DrFerminGarcia @DrJasonAndrade @DhirajGuptaBHRS @SeguraCardio @jvillacastin @smithECGBlog @AskDrShashank @ecgrhythms @iamritu @Hragy




English
Debargha Basuli, MD PhD ретвитнул

#AKIConsultSeries:👨w T2DM➡️🏥 for fever, dysuria and CVA tenderness. On arrival: ⬇️BP, ⬆️Glucose, ⬆️AGMA. Dx UTI + DKA. Tx: Abx + Insulin Pump + 4 L Crystalloid + NE
After resus, pt still oliguric, Cr 3.2. NE 0.7 ug/kg/min,🧠confused, BP 85/62, HR 123, 2L O2. CRT 4 sec
1/12

English
Debargha Basuli, MD PhD ретвитнул

1) Welcome to this new #accredited #tweetorial on best practices for providing #interprofessional, multidisciplinary, and multimodal pharmacologic therapy for patients with #CKD-associated anemia #aCKD. #MedTwitter #FOAMed #nephtwitter @MedTweetorials
English
Debargha Basuli, MD PhD ретвитнул




